氧化低密度脂蛋白与动脉粥样硬化的关系及其防治进展

脑血管疾病是目前世界上主要致死性疾病之一[1],同时也是我国高发病种之一,世界卫生组织2006年12月发布的"全世界脑血管病死亡地图"中明确指出中国是全世界脑血管病死亡率最高的国家,全国每年约有150万人死于脑血管病[2].动脉粥样硬化(atherosclerosis,AS)是所有脑血管意外事件发生的共同基础,主要累及大、中型动脉,导致缺血和损伤,严重威胁人类健康.     

单核细胞趋化蛋白-1与动脉粥样硬化及中医药防治

单核细胞趋化蛋白-1（Monocyte chemoattractant protein-1,MCP-1）属于趋化因子家族中的C-C亚家族成员,大量的研究表明单核细胞的趋化主要是由MCP-1来实现的,它能使血液中的单核细胞迁入内膜下,活化为巨噬细胞,吞噬脂质形成泡沫细胞,在动脉粥样硬化（Artherosclerosis,AS）的早期起着重要作用。同时,在AS发生后期,MCP-1对于促进斑块的不稳定也发挥着作用。     

氧化低密度脂蛋白与动脉粥样硬化的关系及其防治进展

脑血管疾病是目前世界上主要致死性疾病之一,同时也是我国高发病种之一,世界卫生组织2006年12月发布的“全世界脑血管病死亡地图”中明确指出中国是全世界脑血管病死亡率最高的国家,全国每年约有150万人死于脑血管病。动脉粥样硬化（atherosclerosis,AS）是所有脑血管意外事件发生的共同基础,主要累及大、中型动脉,导致缺血和损伤,严重威胁人类健康。     

单核细胞趋化蛋白-1与动脉粥样硬化及中医药防治

单核细胞趋化蛋白-1(Monocyte chemoattractant protein-1,MCP-1)属于趋化因子家族中的C-C亚家族成员,大量的研究表明单核细胞的趋化主要是由MCP-1来实现的,它能使血液中的单核细胞迁入内膜下,活化为巨噬细胞,吞噬脂质形成泡沫细胞,在动脉粥样硬化(Artherosclerosis,AS)的早期起着重要作用。同时,在AS发生后期,MCP-1对于促进斑块的     

复方活血液涂擦结合甲钴胺治疗糖尿病周围神经病变疗效观察

目的观察复方活血液涂擦结合甲钴胺片治疗糖尿病周围神经病变(DPN)的临床疗效。方法将70例DPN患者随机分为治疗组和对照组,每组35例;治疗组给予复方活血液涂擦结合甲钴胺片口服治疗,对照组单纯口服甲钴胺片治疗,疗程8周。观察两组临床疗效和周围神经传导速度变化情况。结果治疗组总有效率为88.24%,对照组为45.71%;组间临床疗效比较,差异有统计学意义(P<0.05);治疗后两组腓总神经、腓肠神经传导速度加快(P<0.05,P<0.01),且治疗组腓肠神经传导速度显著快于对照组(P<0.05)。结论复方活血液涂擦结合甲钴胺片治疗DPN可提高临床疗效和周围神经传导速度。     

稳消Ⅱ方对实验性颈动脉粥样硬化细胞间黏附分子及血管细胞黏附分子-1表达的影响

目的观察稳消Ⅱ方对兔实验性颈动脉粥样硬化细胞间黏附分子-1（ICAM-1）及血管细胞黏附分子-1（VCAM-1）表达的影响,探讨其抗动脉粥样硬化的作用机制。方法将60只健康新西兰大白兔随机分为空白组、干预组（稳消Ⅱ方高、中、低剂量组）、辛伐他汀组、模型组。除空白组外,其余各组均采用高脂饲养及颈动脉内膜球囊损伤法建立兔颈动脉粥样硬化模型。稳消Ⅱ方干预8周后,采用ELISA法检测ICAM-1含量,免疫组化法观察VCAM-1表达。结果与空白组比较,各组ICAM-1、VCAM-1均显著上调（P〈0.05）;与模型组比较,干予组和辛伐他汀组指标均显著下调（P〈0.05）;与辛伐他汀组比较,稳消Ⅱ方低剂量组ICAM-1明显上调（P〈0.05）,余差异无统计学意义;干预组组间比较,高剂量组ICAM-1下调明显大于低剂量组（P〈0.05）,余差异无统计学意义。结论干预组可抑制ICVM-1、VCAM-1的表达,益于动脉粥样硬化斑块的防治与稳定,且与药物剂量之间存在一定的依赖关系。     

Effects of Wenxiao Ⅱ Decoction on the expression of MCP-1 and VCAM-1 in atherosclerotic rabbits

OBJECTIVE:To observe the effects of different doses of Wenxiao Ⅱ Decoction on the expression of monocyte chemoattractant protein-1(MCP-1) and vascular cell adhesion molecule-1(VCAM-1) in an experimental model of atherosclerosis in rabbits and to explore the mechanism by which it alleviates atherosclerosis.METHODS:Sixty 3-4 month-old New Zealand rabbits of both sexes were randomly divided into six groups:simvastain;model;blank;and high-dose,mid-dose,and low-dose Wenxiao Ⅱ Decoction groups.Except for those in the blank group,all rabbits were fed a high-cholesterol diet.Carotid atherosclerosis was established by balloon-induced injury to the endothelium of the carotid artery in conjunction with consumption of a high-cholesterol diet.After 8 weeks,all rabbits were killed to evaluate the expression of MCP-1 and VCAM-1 by immunohistochemical staining.RESULTS:Expressions of MCP-1 and VCAM-1 were significantly decreased in all groups except the blank group compared with the model group(P<0.05).When compared with the simvastain group only variation of MCP-1 expression in low-dose group was not appreciable,and the differences were indistinct(P<0.05).When comparing among Wenxiao Ⅱ Decoction groups,MCP-1 expression in the mid-and high-dose groups was significantly lower than that seen in the low-dose group(P<0.01),but there were no differences among three dosage groups with respect to VCAM-1 expression(P>0.05).CONCLUSION:These data suggested that high,mid,and low doses of Wenxiao Ⅱ Decoction can inhibit the expression of MCP-1 and VCAM-1,which may prevent the formation of or stabilize atherosclerotic plaques.There may be a direct relationship between the dosage of Wenxiao Ⅱ Decoction and its therapeutic efficacy.